Finanzen von Viridian Therapeutics Inc (VRDN)VRDNViridian Therapeutics Inc

Evaluating the bottom line, Viridian Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -44460.56%, while the net margin is -44760.21%. These profitability ratios, combined with a Return on Equity (ROE) of -86.93%, provide a clear picture of how effectively VRDN converts its operational activities into shareholder value.

In the context of the broader market, VRDN competes directly with industry leaders such as SLS and SUPN. With a market capitalization of $2.50B, it holds a significant position in the sector. When comparing efficiency, VRDN's gross margin of 100.00% stands against SLS's N/A and SUPN's 73.07%. Such benchmarking helps identify whether Viridian Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company has shown a gross margin of 100% across recent quarters, indicating strong product profitability, but continues to report significant net losses, with Q2 2026 showing a net income loss of -127,119,000 USD.